Roche has come under fire from the Belgian Competition Authority for “exclusionary practices” relating to biosimilar competition, with the BCA issuing a statement of objections suggesting that the originator abused its dominant position to delay the entry of rituximab and trastuzumab biosimilars between 2017 and 2020. Roche markets the molecules as MabThera and Herceptin respectively.
Belgian Body Hits Out At Roche For Delaying Biosimilar Competition
Competition Authority Cites ‘Exclusionary Practices’ Over Rituximab And Trastuzumab
Roche is in the crosshairs of the Belgian Competition Authority for allegedly delaying the entry of rituximab and trastuzumab biosimilars between 2017 and 2020, after the BCA sent the firm a statement of objections over “exclusionary practices.”
